Business Wire

SAMSUNG-ELECTRONICS

4.6.2021 10:02:05 CEST | Business Wire | Press release

Share
Samsung’s Semiconductor Sites Awarded Industry’s First ‘Triple Standard’ by Carbon Trust

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced that it received the industry’s first Triple Standard for carbon, water and waste by Carbon Trust.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210604005166/en/

Samsung was awarded this certification by reducing the amount of carbon emissions, water use, and waste discharge over the past three years at five operations (Giheung, Hwaseong, Pyeongtaek, Onyang and Cheonan) in Korea and four global manufacturing sites in U.S. and China (Austin, Suzhou, Tianjin and Xi’an). This is a huge feat, considering that it is extremely challenging for semiconductor manufacturing companies to meet all three qualifications at once.

“For decades, Samsung has been striving to incorporate environmental sustainability into every aspect of the semiconductor manufacturing process,” said Seong-dai Jang, senior vice president and head of DS Corporate Sustainability Management Office at Samsung Electronics. “We’ll continue to pursue more environmentally sustainable policies across the entire production and supply chain.”

Samsung has been making various efforts in carbon reduction, water resource conservation and recycling, and has been managing these as important sustainability goals.

Samsung’s efforts to reduce its environmental footprint

  • Greenhouse Gas : Samsung has been sourcing 100-percent renewable energy for its overseas semiconductor operations in the United States and China since 2019, and the company's continued efforts to reduce its carbon footprint also includes optimizing gas use for etching and deposition processes, as well as developing new catalysts for its greenhouse gas reduction equipment. Through these endeavors, Samsung was able to cut about 1.3-million tons1 of carbon emissions in 2020—about 200 million pine trees would be required to absorb the same amount of carbon2 .
  • Water Management : Samsung has been recycling wastewater generated in the process of producing ultra-pure water for equipment such as wet scrubbers and cooling towers. The company has also reduced water usage utilizing its wastewater filtration technology—known as the ‘membrane process’ —to reuse water and optimize manufacturing processes. Equipment operation efficiency has also increased by consolidating wastewater reclamation and reuse systems. As a result, Samsung was able to reuse about 70 million tons of water in 2020, a 12-percent increase compared to 2018~2019, and reduce more than 10 million tons of water usage3 , which is the same amount used for two-million people per month in a metropolitan area in Korea4 .
  • Waste Discharge: Samsung has significantly reduced wastewater sludge5 , which accounts for more than 60-percent of total waste generation, by applying alternative materials and optimizing the amount of materials supplied to particular facilities. In addition, by establishing packaging standards for products brought into the line, the amount of waste from over-packaging has also been reduced. Through all these efforts, Samsung reduced a total of 35,752 tons6 of waste discharged in 2020.

Samsung Electronics strives to incorporate environmental sustainability into everything it does. Samsung’s products are thoughtfully designed to minimize the impact on the environment during their entire lifecycle – from planning and manufacturing to consumption and recycling.

# # #

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com .

1 The amounts stated are converted measurements based on production levels

2 A 30-year-old pine tree can absorb about 6.6 kilograms of carbon dioxide (CO2) per year (Korea Institute of Forest Science)

3 The amounts stated are converted measurements based on production levels

4 Korea Ministry of Environment (2019)

5 Wastewater sludge is a by-product generated in the treatment process of industrial wastewater or sewage.

6 The amounts stated are converted measurements based on production levels

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye